Capital Fund Management S.A. Editas Medicine, Inc. Call Options Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $168,064 - $266,842	-20,200 Reduced 33.17%	40,700 $361,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $280,896 - $448,602	-23,100 Reduced 27.5%	60,900 $745 Million
Q2 2022 Aug 12, 2022	BUY	$9.99 - $21.35 $25,974 - $55,510	2,600 Added 3.19%	84,000 $993,000
Q1 2022 May 12, 2022	BUY	$14.08 - $27.63 $180,224 - $353,664	12,800 Added 18.66%	81,400 $1.55 Million
Q4 2021 Feb 10, 2022	BUY	$26.55 - $40.57 $1.82 Million - $2.78 Million	68,600 New	68,600 $1.82 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $1.65 Million - $2.16 Million	-52,600 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $1.57 Million - $2.32 Million	52,600 New	52,600 $1.74 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.